Annals of Oncology Advance Access originally published online on June 24, 2005
Annals of Oncology 2005 16(9):1514-1523; doi:10.1093/annonc/mdi272
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
Departments of 1 Clinical Oncology 2 Haematology and 3 The Clinical PET Centre, Guy's and St. Thomas’ Hospital, London, UK
* Correspondence to: Dr N. G. Mikhaeel, Department of Clinical Oncology, Lambeth Wing, St. Thomas’ Hospital, London SE1 7EH, UK. Tel: +44 207 188 4219; Email: george.mikhaeel{at}gstt.nhs.uk
Background: Less than 50% of all high-grade non-Hodgkin lymphoma (NHL) patients experience lasting disease-free survival. Risk-adapted treatment strategies require better tools for prediction of outcome. This investigation aimed to assess the value of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) after two to three cycles of chemotherapy for prediction of progression-free survival (PFS) and overall survival (OS).
Patients and methods: One hundred and twenty-one patients with high-grade NHL underwent FDG-PET. The therapy response on FDG-PET was correlated to PFS and OS using Kaplan–Meier survival analysis. Cox regression analyses were employed to test for independence of known pretreatment prognostic factors.
Results: Fifty FDG-PET scans were negative, 19 scans showed minimal residual uptake (MRU), and 52 scans were positive. The estimated 5 year PFS was 88.8% for the PET-negative group, 59.3% for the MRU group, and 16.2% for the PET-positive group. Kaplan–Meier analyses showed strong associations between FDG-PET results and PFS (P <0.0001) and OS (P <0.01). Early interim FDG-PET was independent of the other prognostic factors.
Conclusions: Early interim FDG-PET is an accurate and independent predictor of PFS and OS. An early assessment of chemotherapy response with FDG-PET could provide the basis for selection of patients for alternative therapeutic strategies.
Key words: fluorodeoxyglucose F18, non-Hodgkin lymphoma, positron emission tomography, prognosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. J. Horning, M. E. Juweid, H. Schoder, G. Wiseman, A. McMillan, L. J. Swinnen, R. Advani, R. Gascoyne, and A. Quon Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study Blood, January 28, 2010; 115(4): 775 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Cronin, R. Swords, M. T. Truong, C. Viswanathan, E. Rohren, F. J. Giles, M. O'Dwyer, and J. F. Bruzzi Clinical Utility of PET/CT in Lymphoma Am. J. Roentgenol., January 1, 2010; 194(1): W91 - W103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Furth, I. G. Steffen, H. Amthauer, J. Ruf, D. Misch, S. Schonberger, C. Kobe, T. Denecke, B. Stover, H. Hautzel, et al. Early and Late Therapy Response Assessment With [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial J. Clin. Oncol., September 10, 2009; 27(26): 4385 - 4391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Markova, C. Kobe, M. Skopalova, K. Klaskova, K. Dedeckova, A. Plutschow, H. T. Eich, M. Dietlein, A. Engert, and T. Kozak FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value Ann. Onc., July 1, 2009; 20(7): 1270 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber Assessing Tumor Response to Therapy J. Nucl. Med., May 1, 2009; 50(Suppl_1): 1S - 10S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hutchings and S. F. Barrington PET/CT for Therapy Response Assessment in Lymphoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Terasawa, J. Lau, S. Bardet, O. Couturier, T. Hotta, M. Hutchings, T. Nihashi, and H. Nagai Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review J. Clin. Oncol., April 10, 2009; 27(11): 1906 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Luigi Zinzani, V. Stefoni, M. Tani, S. Fanti, G. Musuraca, P. Castellucci, E. Marchi, M. Fina, V. Ambrosini, C. Pellegrini, et al. Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma J. Clin. Oncol., April 10, 2009; 27(11): 1781 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Itti, C. Lin, J. Dupuis, G. Paone, D. Capacchione, A. Rahmouni, C. Haioun, and M. Meignan Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy J. Nucl. Med., April 1, 2009; 50(4): 527 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dupuis, E. Itti, A. Rahmouni, F. Hemery, C. Gisselbrecht, C. Lin, C. Copie-Bergman, K. Belhadj, T. El Gnaoui, I. Gaillard, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria Ann. Onc., March 1, 2009; 20(3): 503 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Han, M. P. Escalon, B. Hsiao, A. Serafini, and I. S. Lossos High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens Ann. Onc., February 1, 2009; 20(2): 309 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A V Martin and B Sharma Positron emission tomography and CT in the management of lymphoma Imaging, September 1, 2008; 20(3): 169 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bodet-Milin, F. Kraeber-Bodere, B. Dupas, F. Morschhauser, T. Gastinne, S. Le Gouill, L. Campion, J.-L. Harousseau, W. A. Wegener, D. M. Goldenberg, et al. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography Haematologica, March 1, 2008; 93(3): 390 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Seam, M. E. Juweid, and B. D. Cheson The role of FDG-PET scans in patients with lymphoma Blood, November 15, 2007; 110(10): 3507 - 3516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber 18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative? J. Nucl. Med., October 1, 2007; 48(10): 1580 - 1582. [Full Text] [PDF]
|
|
|
|
|
|
S. Kako, K. Izutsu, Y. Ota, Y. Minatani, M. Sugaya, T. Momose, K. Ohtomo, Y. Kanda, S. Chiba, T. Motokura, et al. FDG-PET in T-cell and NK-cell neoplasms Ann. Onc., October 1, 2007; 18(10): 1685 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, J. Dupuis, G. Paone, J.-N. Talbot, A. Rahmouni, and M. Meignan Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis J. Nucl. Med., October 1, 2007; 48(10): 1626 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al. Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma Clin. Cancer Res., June 15, 2007; 13(12): 3552 - 3558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dupuis, P. Gaulard, F. Hemery, E. Itti, C. Gisselbrecht, A. Rahmouni, C. Copie-Bergman, J. Briere, T. E. Gnaoui, I. Gaillard, et al. Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma Haematologica, June 1, 2007; 92(6): 778 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Strobel, N. Schaefer, C Renner, P Veit-Haibach, D Husarik, A. Koma, and T. Hany Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients? Ann. Onc., April 1, 2007; 18(4): 658 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al. Revised Response Criteria for Malignant Lymphoma J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Schot, J. M. Zijlstra, W. J. Sluiter, G. W. van Imhoff, J. Pruim, W. Vaalburg, and E. Vellenga Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma Blood, January 15, 2007; 109(2): 486 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. L. Kasamon, R. J. Jones, and R. L. Wahl Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. S. Jhanwar and D. J. Straus The Role of PET in Lymphoma J. Nucl. Med., August 1, 2006; 47(8): 1326 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Zinzani, M. Tani, S. Fanti, L. Alinari, G. Musuraca, E. Marchi, V. Stefoni, P. Castellucci, M. Fina, M. Farshad, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients Ann. Onc., August 1, 2006; 17(8): 1296 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber Positron Emission Tomography As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hutchings, A. Loft, M. Hansen, L. M. Pedersen, T. Buhl, J. Jurlander, S. Buus, S. Keiding, F. D'Amore, A.-M. Boesen, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma Blood, January 1, 2006; 107(1): 52 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W A Weber PET for response assessment in oncology: radiotherapy and chemotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49. [Abstract] [Full Text] [PDF]
|
|